AMEI's Current Trends in Diagnosis & Treatment

Register      Login

VOLUME 6 , ISSUE 2 ( July-December, 2022 ) > List of Articles


Tyrosine Kinase Inhibitor (Erlotinib)-induced Papulopustular Rash

Rajeev Gupta, Shveta Mahajan, Manavdeep Kaur

Keywords : Erlotinib, Epidermal growth factor receptor, Papulopustular

Citation Information : Gupta R, Mahajan S, Kaur M. Tyrosine Kinase Inhibitor (Erlotinib)-induced Papulopustular Rash. Curr Trends Diagn Treat 2022; 6 (2):39-40.

DOI: 10.5005/jp-journals-10055-0141

License: CC BY-NC 4.0

Published Online: 21-12-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Erlotinib is a reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, competitively inhibiting adenosine triphosphate (ATP) binding at the active site of the kinase. It is approved for treatment of advanced and metastatic cancers. The objective of this report is to find out the cause of the papulopustular lesion while the patient is on tyrosine kinase inhibitor. Our 57-year-old male known case of metastatic pancreatic cancer is on injection gemcitabine 1400 mg (D1 and D8), injection carboplatin 450 mg (D1), and tablet erlotinib 150 mg OD since 1.5 months and after 3 weeks of therapy he developed papulopustular lesions over legs and face which is a side effect of tablet erlotinib and thus it is discontinued and now the patient is being treated for papulopustular lesion by oral and topical antibiotics.

  1. Goodman LS. Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996.
  2. Owczarczyk–Saczonek A, Witmanowski H, Placek W. Acneiform rash during lung cancer therapy with erlotinib (Tarceva®). Postępy Dermat Alergol 2013;30(3):195. DOI: 10.5114/pdia.2013.35624.
  3. Abdullah SE, Haigentz M, Piperdi B. Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: Pathophysiology and management. Chemotherapy Research and Practice 2012;2012. DOI: 10.1155/2012/351210.
  4. Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013;5(199):199ra111. DOI: 10.1126/scitranslmed.3005886.
  5. Fabbrocini G, Panariello L, Caro G, et al. Acneiform rash induced by EGFR inhibitors: Review of the literature and new insights. Skin Appendage Disord 2015;1(1):31–37. DOI: 10.1159/000371821.
  6. Tsimboukis S, Merikas I, Karapanagiotou EM, et al. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: Pathogenesis, clinical significance, and management. Clinical Lung Cancer 2009; 10(2):106–111. DOI: 10.3816/CLC.2009.n.013.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.